CANbridge Approved to Launch Pruritus Therapy for Alagille Syndrome in China
publication date: Jun 2, 2023
Beijing CANbridge Pharma was approved to launch Maralixibat Chloride Oral Solution (Livmarli®) in China to treat cholestatic pruritus in patients at least one year old with Alagille syndrome. Livmarli (maralixibat) inhibits ileal bile acid transporters (IBAT), blocking bile circulation and lowering bile acid levels in the liver and serum. This reduces liver injury and relieves pruritus. Livmarli is the only medication approved in China, the US and EU to treat Alagille syndrome cholestatic pruritus. CANbridge, a rare disease company, acquired China rights for Livmarli from Mirum Pharma, a San Francisco-area biopharma. More details....
Stock Symbol: (HK: 1228)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.